Yaoguang Feng

Dec 9, 2024 | dx.doi.org | Hongchang Wu |Ting Wang |Di Wu |Yaoguang Feng

Dec 9, 2024 | pubs.acs.org | Hongchang Wu |Ting Wang |Di Wu |Yaoguang Feng

Nov 11, 2024 | pubs.acs.org | Di Wu |Hongxun Hao |Shuyu Li |Yaoguang Feng

Nov 11, 2024 | dx.doi.org | Di Wu |Hongxun Hao |Shuyu Li |Yaoguang Feng

Aug 15, 2024 | pubs.rsc.org | Yaoguang Feng |Hui Wang |Di Wu |Kui Chen

Polymorph transformation of solid drugs and inhibiting strategies Metastable forms and amorphous forms exhibit higher solubility and dissolution rates compared to stable crystalline forms, making them viable options for pharmaceuticals with low solubility. However, the use of metastable forms and amorphous forms may result in polymorph transformation in pharmaceutical manufacture and storage, which will reduce their bioavailability.